Evidence map›Paper›PMID 38468126›Full record

ArticleCNS neuroscience & therapeutics2024

Hyperforin ameliorates neuroinflammation and white matter lesions by regulating microglial VEGFR

Xin Gao, Jingjing Chen, Ge Yin, Yanqun Liu, Zhengsheng Gu, Rui Sun, Xu Sun, Xuehao Jiao, Ling Wang, Nuo Wang and 4 more

Open access · goldAbstract read
In one paragraph

Article in CNS neuroscience & therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
4.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Roles of Microglia in Cerebral Small Vessel Disease.CNS neuroscience & therapeutics · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Xin GaoDepartment of Neurology, Shanghai Changhai Hospital, Second Military Medical University/Naval Medical University, Shanghai, China.ORCID 0009-0001-5965-9817
Jingjing ChenDepartment of Neurology, Shanghai Changhai Hospital, Second Military Medical University/Naval Medical University, Shanghai, China.
Ge YinDepartment of Neurology, Shanghai Changhai Hospital, Second Military Medical University/Naval Medical University, Shanghai, China.
Yanqun LiuDepartment of Neurology, Shanghai Changhai Hospital, Second Military Medical University/Naval Medical University, Shanghai, China.
Zhengsheng GuDepartment of Neurology, Shanghai Changhai Hospital, Second Military Medical University/Naval Medical University, Shanghai, China.
Rui SunDepartment of Neurology, Shanghai Changhai Hospital, Second Military Medical University/Naval Medical University, Shanghai, China.
Xu SunDepartment of Neurology, Shanghai Changhai Hospital, Second Military Medical University/Naval Medical University, Shanghai, China.
Xuehao JiaoDepartment of Neurology, Shanghai Changhai Hospital, Second Military Medical University/Naval Medical University, Shanghai, China.
Ling WangDepartment of Neurology, Shanghai Changhai Hospital, Second Military Medical University/Naval Medical University, Shanghai, China.
Nuo WangDepartment of Neurology, Shanghai Changhai Hospital, Second Military Medical University/Naval Medical University, Shanghai, China.
Yanbo ZhangDepartment of Psychiatry, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
Yuting KanDepartment of Neurology, Shanghai Changhai Hospital, Second Military Medical University/Naval Medical University, Shanghai, China.
Xiaoying BiDepartment of Neurology, Shanghai Changhai Hospital, Second Military Medical University/Naval Medical University, Shanghai, China.
Bingying DuDepartment of Neurology, Shanghai Changhai Hospital, Second Military Medical University/Naval Medical University, Shanghai, China.ORCID 0000-0003-3124-780X
Second Military Medical University · CNUniversity of Alberta · CA

Funding

National Natural Science Foundation of China 81871040National Natural Science Foundation of China 82101563
6 · The paper itself

Abstract

aimTo explore the neuroprotective potential of hyperforin and elucidate its underlying molecular mechanisms involved in its therapeutic effects against vascular cognitive impairment (VCI).

methodsThe active compounds and possible targets of Hypericum perforatum L. that may be effective against VCI were found by network pharmacology in this research. We utilized bilateral common carotid artery occlusion (BCCAO) surgery to induce a VCI mouse model. Morris water maze (MWM) and Y-maze tests were used to assess VCI mice's cognitive abilities following treatment with hyperforin. To evaluate white matter lesions (WMLs), we utilized Luxol fast blue (LFB) stain and immunofluorescence (IF). Neuroinflammation was assessed using IF, western blot (WB), and enzyme-linked immunosorbent assay (ELISA). The effects of hyperforin on microglia were investigated by subjecting the BV2 microglial cell line to oxygen-glucose deprivation/reperfusion (OGD/R) stimulation. The expressions of VEGFR

resultsThe VEGFR

conclusionHyperforin effectively modulated microglial M1 polarization and neuroinflammation by inhibiting the VEGFR

Indexed as

Cognitive DysfunctionTerpenesWhite MatterAnimalsInterleukin-6MiceMicrogliaNeuroinflammatory DiseasesPhloroglucinolTumor Necrosis Factor-alphahyperforinInterleukin-6PhloroglucinolTerpenesTumor Necrosis Factor-alphahyperforinmicroglia polarizationneuroinflammationvascular cognitive impairmentwhite matter lesions

Identifiers

PMID38468126
PMCPMC10927933
OpenAlexW4392712712

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.